Table of Contents
The largest middleman in the prescription drug supply chain, CVS Health, has entered the specialty drug manufacturing business. This move has raised concerns about potential conflicts of interest, as CVS is also a pharmacy benefit manager (PBM) that negotiates with drug manufacturers. Regulators are taking a hard look at PBMs, with the Federal Trade Commission inviting the public to submit complaints about them. Critics worry that CVS's entry into biosimilars may erode competition in the long run and bring drug costs back up. Despite this, CVS claims that their focus is on lowering drug pricing for their clients and patients. The move has sparked a debate about the impact of PBMs on the pharmaceutical market and the potential consequences of their expansion into drug manufacturing.
